2023 - Research.com Medicine in Denmark Leader Award
2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in Denmark Leader Award
2021 - Canada Gairdner International Award
2020 - Warren Alpert Foundation Prize For identifying Glucagon-like peptides and leading the field with studies extending from cells to humans, culminating in the development of these peptides as therapeutic agents for treating diabetes and short bowel syndrome.
His primary scientific interests are in Internal medicine, Endocrinology, Glucagon-like peptide-1, Insulin and Glucagon. His work in Postprandial, Gastric emptying, Glucagon secretion, Gastrointestinal hormone and Hormone is related to Internal medicine. His research investigates the connection between Postprandial and topics such as Appetite that intersect with issues in Ghrelin.
His study involves Incretin, Diabetes mellitus, Type 2 diabetes, Pancreatic hormone and Gastric inhibitory polypeptide, a branch of Endocrinology. His research integrates issues of Small intestine, Secretion, Somatostatin, Peptide and Dipeptidyl peptidase in his study of Glucagon-like peptide-1. His research investigates the link between Glucagon and topics such as Proglucagon that cross with problems in Glucagon-like peptide-2, Enteroglucagon and Receptor.
Jens J. Holst spends much of his time researching Internal medicine, Endocrinology, Insulin, Glucagon and Glucagon-like peptide-1. Jens J. Holst combines subjects such as Diabetes mellitus and Type 2 diabetes with his study of Internal medicine. Jens J. Holst has included themes like Weight loss and Type 2 Diabetes Mellitus in his Type 2 diabetes study.
His studies link Gastric emptying with Endocrinology. His Glucagon research is multidisciplinary, relying on both Glucagon-like peptide-2, Proglucagon, Somatostatin and Peptide hormone. His Glucagon-like peptide-1 research is multidisciplinary, incorporating perspectives in Gastrointestinal hormone and Receptor.
His scientific interests lie mostly in Internal medicine, Endocrinology, Glucagon, Postprandial and Insulin. His Internal medicine research includes elements of Diabetes mellitus, Type 2 diabetes and Crossover study. The Type 1 diabetes and Hypoglycemia research Jens J. Holst does as part of his general Diabetes mellitus study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
While the research belongs to areas of Endocrinology, Jens J. Holst spends his time largely on the problem of Receptor, intersecting his research to questions surrounding Pharmacology. The concepts of his Postprandial study are interwoven with issues in Meal, Gastric emptying, Weight loss, Bile acid and Glycemic. His biological study focuses on Insulin resistance.
His primary areas of study are Internal medicine, Endocrinology, Glucagon, Postprandial and Hormone. His research on Internal medicine focuses in particular on Insulin. His Endocrinology study integrates concerns from other disciplines, such as Receptor and Antagonist.
His research in Glucagon focuses on subjects like Alpha cell, which are connected to Lipid metabolism. His Postprandial research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Physiology of Glucagon-like Peptide 1
Jens Juul Holst.
Physiological Reviews (2007)
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
M A Nauck;M M Heimesaat;C Orskov;J J Holst.
Journal of Clinical Investigation (1993)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
Mette Zander;Mette Zander;Sten Madsbad;Jan Lysgaard Madsen;Jens Juul Holst.
The Lancet (2002)
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint;A Raben;A Astrup;J J Holst.
Journal of Clinical Investigation (1998)
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
M. A. Nauck;N. Kleine;C. Orskov;J. J. Holst.
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
Mai-Britt Toft-Nielsen;Mette B. Damholt;Sten Madsbad;Linda M. Hilsted.
The Journal of Clinical Endocrinology and Metabolism (2001)
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
Tina Vilsbøll;Thure Krarup;Carolyn F. Deacon;Sten Madsbad.
Type 2 diabetes mellitus.
Ralph A. DeFronzo;Ele Ferrannini;Leif Groop;Robert R. Henry.
Nature Reviews Disease Primers (2015)
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects
Carolyn F Deacon;Michael A Nauck;Maibritt Toft-Nielsen;Lone Pridal.
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
M Gutniak;C Orskov;J J Holst;B Ahrén.
The New England Journal of Medicine (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: